Zoetis Launches Stronghold® Plus (selamectin/sarolaner) in Europe


  • A new topical parasiticide for cats combines the active ingredient in Stronghold – selamectin – with sarolaner for broadened and extended protection
  • Zoetis introduces first combination product building on its sarolaner platform in the $4.2 billion companion animal parasiticide market


ROME, ITALY – March 27, 2017 – Zoetis Inc.  today announced the European launch of Stronghold®Plus (selamectin/sarolaner), a topical combination of parasiticides that treats ticks, fleas, ear mites, lice and GI nematodes and prevents heartworm disease in cats.

Veterinarians across the European Union now have a treatment choice that leverages the benefits of sarolaner, a new innovation in the class of isoxazolines, without sacrificing the broad spectrum protection, safety, or ease of use they expect from selamectin.

”The launch of  Stronghold Plus enables Zoetis to offer veterinarians in the European Union a new topical choice that treats the parasites commonly presenting a threat to cats with one convenient monthly dose,” said Clint Lewis, Executive Vice President and President International Operations. “For the first time, we have combined our new, versatile parasiticide sarolaner with the active ingredient in Stronghold, selamectin, resulting in the first approval of sarolaner for use in cats. We see sarolaner as a promising platform for future product lines and lifecycle innovations and are pleased with the positive data that sarolaner and its combination continue to generate in studies.”

The market for companion animal parasitic medicines was valued at more than $4.2 billion in 2015, with a compound annual growth rate of about 5% over the previous five years, according to Vetnosis1.

Domenico Otranto, Professor of Parasitology at Bari University in Italy, who recently reviewed the product data of Stronghold Plus, said: “A number of laboratory and field studies show the efficacy of the single spot-on application of Stronghold Plus for at least one month. Veterinarians in Europe now have a very effective option for the treatment and control of four prominent species of ticks commonly found on cats while maintaining proven efficacy against fleas, GI worms, heartworms, ear mites and lice. Ultimately, pet owners and practitioners have a new tool for improving health and welfare of cats.”


About Stronghold Plus product efficacy and safety:

The active substances in Stronghold Plus are selamectin and sarolaner, a new combination of parasiticides. Selamectin has adulticidal, ovicidal and larvicidal activity against fleas (Ctenocephalides spp.). Selamectin is also active against ear mites, lice, gastrointestinal nematodes and prevents heartworm disease through its efficacy against Dirofilaria immitis larvae. Sarolaner is a new acaricide and insecticide belonging to the isoxazoline class: it is efficacious against ticks, fleas and mites.

In clinical studies, the high and consistent efficacy was demonstrated against fleas and ticks, as well as the high efficacy against lice, mites, gastro-intestinal nematodes and heartworm.  The most common side effects of Stronghold Plus are mild and transient pruritus at the application site. Mild to moderate alopecia at the application site, erythema and drooling have been uncommonly observed.

Dr Thomas Geurden, Associate Director of Veterinary Research and Development at Zoetis, said: “Stronghold Plus was entirely discovered and developed by Zoetis scientists. It provides fast, sustained protection from the fleas and ticks most often found on cats. The combined action of sarolaner and selamectin allows Stronghold Plus to kill four species of ticks, and it lengthens the duration of protection against fleas to five full weeks with no drop in efficacy at the end of the dosing period – all without sacrificing protection from other important internal and external feline parasites. We’re excited to be able to bring this innovation to veterinarians across Europe in the second quarter.


Prescribing Information:

Stronghold Plus should be administered as a single spot-on (topical) application in accordance with the bodyweight of the cat available on the product label.


Read the peer-reviewed study in Veterinary Parasitology



To view a replay of the media webinar, visit:



Expected European Product Launch Dates

Benelux: May 9th

Italy: middle of June

Germany: pre-launch March 23; available May 9th

France : middle of May